Tarceva
Erlotinib tablets for non-small cell lung and pancreatic cancer. It targets a protein that helps these cancers grow.
- Category
- Oncology Support
- Active ingredient
- Erlotinib
- Route
- Oral use
- Form
- Film-coated tablet
- Strengths
- 100mg
This listing uses Tarceva as a reference name. A generic equivalent is supplied; its exact brand and manufacturer are confirmed before supply.
Prescription and consultation requirements for Tarceva vary by destination and are determined by the fulfilment partner.
Tarceva details
- Conditions
- Non-small Cell Lung Cancer · Pancreatic Cancer
- Therapeutic class
- Protein kinase inhibitors
- Pharmacological class
- Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
- Contraindications
- hypersensitivity to erlotinib or any excipients
- Minor side effects
- rash; diarrhoea; decreased appetite; fatigue
- Moderate side effects
- nausea; vomiting; stomatitis; dry skin; pruritus; conjunctivitis
- Dosage forms
- Film-coated tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Originator
- Cheplapharm Registration GmbH
- Storage instructions
- This medicinal product does not require any special storage conditions.
- Drug interactions
- CYP3A4 inhibitors; CYP3A4 inducers; warfarin; proton pump inhibitors; statins
- Age restrictions
- Safety and efficacy in children and adolescents have not been established.
Precautions and warnings
should be prescribed by a physician experienced in the use of anticancer medicines; EGFR mutation testing should be performed before initiation in NSCLC; patients should stop smoking as smoking decreases erlotinib plasma concentrations; interstitial lung disease has been reported; discontinue if new or progressive pulmonary symptoms develop; gastrointestinal perforation risk; discontinue if it occurs; severe bullous, blistering or exfoliative skin conditions have been reported; hepatic function should be monitored periodically; dose reduction or interruption may be required for severe adverse reactions
Serious side effects
interstitial lung disease, requires immediate medical attention; gastrointestinal perforation, requires immediate medical attention; severe hepatic failure, requires immediate medical attention; corneal perforation, requires immediate medical attention; stevens-Johnson syndrome, requires immediate medical attention
Patient summary
Erlotinib tablets for non-small cell lung and pancreatic cancer. It targets a protein that helps these cancers grow.
Mechanism of action
Tarceva contains erlotinib, a medicine that targets a protein called epidermal growth factor receptor (EGFR) found on the surface of some cancer cells. By blocking EGFR, Tarceva prevents cancer cells from receiving the signals they need to grow and spread. It is used to treat certain types of non-small cell lung cancer and, in combination with another medicine called gemcitabine, to treat metastatic pancreatic cancer.
Pregnancy and breastfeeding
Pregnancy: Should not be used during pregnancy unless clearly necessary. Women of childbearing potential must use effective contraception during treatment and for at least 2 weeks after the last dose. Breastfeeding: Should be discontinued during treatment.
What you will receive
Tarceva is used here as a reference originator brand name to identify the medicine. We are not affiliated with the brand owner, and this listing does not offer the originator product.
- The supplied product is a generic equivalent containing Erlotinib, not the originator brand shown as the reference.
- The exact generic brand, manufacturer and dispatch location are confirmed based on the product, destination and available manufacturer or partner warehouse.
- Check the final product details at checkout before confirming an order.